Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesPrimary Antifungal Prophylaxis in Adult Hematopoietic Stem Cell Transplant Recipients: Current Therapeutic Concepts
Pharmacotherapy, 10/29/09
McCoy D et al. – Fluconazole remains the gold standard for primary prophylaxis in autologous HSCT recipients. For allogeneic HSCT recipients, the agent chosen for prophylaxis must be based on the patient's risk factors for IFIs. In low–risk patients, fluconazole is an appropriate agent to use for primary prophylaxis immediately after transplantation. However, in allogeneic HSCT recipients who develop complications, such as graft failure, graft–versus–host disease, or cytomegalovirus infection, prophylaxis with a mould–active agent should be used.
Today in Antimicrobials...keeping you current
Receive free subspecialty "5-minute updates" via email
Antibiotic Prophylaxis and Recurrent Urinary Tract Infection in Children
New England Journal of Medicine, 10/29/09
Topical Antimicrobial Therapy for Treating Chronic Wounds
Clinical Infectious Diseases, 10/29/09
Chronic Obstructive Pulmonary Disease: Role of Bacteria and Updated Guide to Antibacterial Selection in the Older Patient
Drugs & Aging, 11/25/09
Sponsor
Article Search
Sponsor